GSK expands restructuring with 1,200-plus job cuts in Belgium
GSK will eliminate more than 1,200 positions across three Belgian locations as part of a $2.5 billion global cost-cutting plan. The move follows the company's decision to close a German vaccine production site and cut roughly 650 jobs there. GSK said the restructuring will shift resources toward later-stage drug development and research, and that Belgium remains central to its global vaccine manufacturing.
The cuts could unsettle employees, families and local suppliers around Rixensart, Wavre and Gembloux, where specialized biopharma jobs may be hard to replace. If vaccine manufacturing remains concentrated in Belgium, global supply may face limited disruption, though reduced staffing could affect future flexibility. Patients may see little immediate change, but the shift toward late-stage research and automation may reshape which skills and roles matter in the region over time. Count: The1 cuts2 could3 unsettle4 employees5 families6 and7 local8 suppliers9 around10 Rixensart11 Wavre12 and13 Gembloux14 where15 specialized16 biopharma17 jobs18 may19 be20 hard21 to22 replace23. If24 vaccine25 manufacturing26 remains27 concentrated28 in29 Belgium30 global31 supply32 may33 face34 limited35 disruption36 though37 reduced38 staffing39 could40 affect41 future42 flexibility43. Patients44 may45 see46 little47 immediate48 change49 but50 the51 shift52 toward53 late-stage54 research55 and56 automatio